JAK Inhibitors and Management of Atopic Dermatitis: A Comprehensive Activity for Pharmacists

Program Description

Atopic dermatitis (AD) often presents in childhood but can be a chronic condition that persists through adolescence and into adulthood. AD is characterized by bouts of recurrent inflammation and skin damage resulting in itching and dryness that negatively impacts patients’ quality of life. While there is currently no cure for AD, conventional management focuses on the combined use of nonpharmacologic factors such as avoiding irritants and systemic treatments of topical therapies with corticosteroids to address AD flares. Several Janus kinase (JAK) inhibitors have recently been approved, and other emerging agents and medication classes are under investigation for the management of AD. As the JAK inhibitors enter the treatment paradigm for AD, pharmacists will have an important role in counseling patients about JAK inhibitors, including administration and potential adverse effects. This activity will highlight clinical safety and efficacy data supporting the use of JAK inhibitors as well as counseling points for patients to self-manage symptoms of AD. The pharmacist’s involvement in creating individualized treatment regimens supporting appropriate use of emerging JAK inhibitors will be discussed.

Target audience: Specialty pharmacists

Type of activity: Application
Release date: March 31, 2022
Expiration date: March 31, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the burden of atopic dermatitis (AD) and the treatment strategies to manage the disease
• Analyze the latest safety and efficacy data of the emerging Janus kinase (JAK) inhibitors for the treatment of AD
• Identify the role of pharmacists when addressing the challenges of AD treatment

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-157-H01-P. The activity is available for CE credit through March 31, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Megan Schneider, PharmD, BS

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms